| Followers | 0 |
| Posts | 3251 |
| Boards Moderated | 0 |
| Alias Born | 04/21/2025 |
Wednesday, December 31, 2025 5:04:21 PM
That makes no sense, and that is NOT what RA's do.
MHRA is not providing cover, the sent it to CHM because they couldn't approve, CHM took about 10 months to advise and they will either tell MHRA to approve or they will allow NWBO a chance to appeal a negative opinion. That's it, text book, no drama. The problem is that NW never informed SHs that it was referred to CHM, which I said back in March and got sh*t for saying so on this board. Now that the CHM minutes are out, I have been proven 100% correct.
Any real CEO would have informed SHs of that CHM referral news back in March, but the scoundrel needed to keep selling shares and raising money.
These are my opinions, time will tell. Do your own DD.
MHRA is not providing cover, the sent it to CHM because they couldn't approve, CHM took about 10 months to advise and they will either tell MHRA to approve or they will allow NWBO a chance to appeal a negative opinion. That's it, text book, no drama. The problem is that NW never informed SHs that it was referred to CHM, which I said back in March and got sh*t for saying so on this board. Now that the CHM minutes are out, I have been proven 100% correct.
Any real CEO would have informed SHs of that CHM referral news back in March, but the scoundrel needed to keep selling shares and raising money.
These are my opinions, time will tell. Do your own DD.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
